HRG038
HRG038 is a covalent CUL4DCAF16-base PROTAC-liked BRD4 degrader. HRG038 induces proteasome- and Cullin E3 ligase-dependent degradation, covalently targets cysteine residue C173 on DCAF16 to mediate BRD4 degradation, and induces reduction in BRD3 levels. HRG038 shows selective loss of the short BRD4 isoform over the long isoform in non-cancer cells, degrades both BRD4 isoforms in breast cancer cells, and does not impair cell viability in non-cancer cells. HRG038 can be used for the research of breast cancer.
For research use only. We do not sell to patients.
- Formula: C34H31Cl2N11O3S
- Molecular Weight:744.65
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
BRD4 |
In Vitro
HRG038 (0.001-5 μM; 24 h) potently degrades both long and short BRD4 isoforms in MDA-MB-231 breast cancer cells[1].
HRG038 (1 μM; 24 h) moderately selectively degrades BRD4 and induces a 21% reduction in BRD3 levels in MDA-MB-231 cells, with 89 additional proteins significantly downregulated[1].
HRG038 (1 μM; 24 h) induces 84% loss of BRD4 with selective degradation of the short isoform over the long isoform in HEK293T cells, without impairing cell viability[1].
HRG038 (100 nM; 24 h)-mediated BRD4 degradation in HEK293T cells is proteasome- and Cullin E3 ligase-dependent, as pretreatment with 1 μM Bortezomib (HY-10227) or 1 μM Pevonedistat (HY-70062) for 1 h attenuates degradation[1].
HRG038 (100 nM; 24 h)-mediated BRD4 degradation is fully attenuated in CUL4DCAF16 knockout HEK293T cells, confirming dependence on CUL4DCAF16 for degradation[1].
HRG038 (100 nM; 24 h)-mediated BRD4 degradation in CUL4DCAF16 knockout HEK293T cells requires the C173 cysteine residue of CUL4DCAF16, as mutation to serine (C173S) completely attenuates degradation, while C58S, C119S, and C178S mutations do not[1].
HRG038 exhibits high reactivity with glutathione, with a half-life of 34 min in a cell-free system[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HEK293T cells
-
Concentration:1 μM
-
Incubation Time:24 h
-
Result:Induced an 84% loss of BRD4, with selective degradation of the short BRD4 isoform over the long BRD4 isoform.
Did not impair cell viability in HEK293T cells.
-
Cell Line:HEK293T cells
-
Concentration:0.001 μM, 0.01 μM, 0.1 μM, 1 μM, 5 μM
-
Incubation Time:24 h
-
Result:Exhibited nanomolar potency for selective degradation of the short BRD4 isoform over the long BRD4 isoform.
-
Cell Line:MDA-MB-231 breast cancer cells
-
Concentration:0.001 μM, 0.01 μM, 0.1 μM, 1 μM, 5 μM
-
Incubation Time:24 h
-
Result:Potently degraded both long and short isoforms of BRD4.
-
Cell Line:HEK293T cells
-
Concentration:100 nM
-
Incubation Time:24 h; 1 h (Bortezomib pretreatment); 1 h (Pevonedistat pretreatment)
-
Result:Showed attenuated BRD4-degrading activity when cells were pretreated with bortezomib or pevonedistat, demonstrating proteasome- and Cullin E3 ligase-dependence.
-
Cell Line:CUL4DCAF16 wild-type and knockout HEK293T cells
-
Concentration:100 nM
-
Incubation Time:24 h
-
Result:Failed to degrade BRD4 in CUL4DCAF16 knockout cells, with its BRD4-degrading activity fully attenuated.
-
Cell Line:CUL4DCAF16 knockout HEK293T cells expressing FLAG-CUL4DCAF16 wild-type or mutant constructs
-
Concentration:100 nM
-
Incubation Time:24 h
-
Result:Lost BRD4-degrading activity in cells expressing the C173 to serine (C173S) mutant, while retaining activity in cells expressing C58S, C119S, and C178S mutations.
Identified C173 as its primary modification site on CUL4DCAF16 via mass spectrometry mapping.
Chemical Information
-
Molecular Weight 744.65
-
Formula C34H31Cl2N11O3S
-
SMILES
CC(N1C(S2)=C(C(C3=CC=C(Cl)C=C3)=N4)C(C)=C2C)=NN=C1[C@@H]4CC(N(CC5)CCN5C(/C=C/C(NC(C=N6)=CC(Cl)=C6N7N=CC=N7)=O)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)